Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study

Autor: Yi Ho, Ching Hung Wang, Shuo Ju Chiang, Yow Shieng Uang, Hsiu Chen Lin, Li Hsuan Wang, Masao Daimon
Rok vydání: 2017
Předmět:
Male
musculoskeletal diseases
congenital
hereditary
and neonatal diseases and abnormalities
medicine.medical_specialty
Gout
Allopurinol
Taiwan
Coronary Disease
030204 cardiovascular system & hematology
Drug Administration Schedule
Gout Suppressants
Coronary artery disease
03 medical and health sciences
Benzbromarone
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Humans
030212 general & internal medicine
Myocardial infarction
Risk factor
Dose-Response Relationship
Drug
business.industry
Incidence
Hazard ratio
nutritional and metabolic diseases
Middle Aged
Uricosuric Agents
medicine.disease
Uric Acid
Surgery
Treatment Outcome
chemistry
Population Surveillance
Drug Therapy
Combination
Female
Cardiology and Cardiovascular Medicine
business
Kidney disease
medicine.drug
Zdroj: International Journal of Cardiology. 233:85-90
ISSN: 0167-5273
Popis: Background The effect of gout on the risk of developing coronary artery disease (CAD) is uncertain. Some studies have found that gout is a risk factor for acute myocardial infarction. This study examined the changes in risk of CAD in gout patients taking allopurinol and/or benzbromarone, and analyzed the dose-response relationship of both drugs with CAD incidence. Methods The medical records of one million subjects from 2000 to 2011 were provided by the Taiwan National Health Insurance Research Database. Cox proportional hazard ratio was used to compare the risk of CAD in gout patients taking allopurinol or/and benzbromarone with those taking neither drug. Hazard ratios (HR) were adjusted for possible confounding factors, including age, gender, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, and relevant medications. Results Of 8047 gout patients, 1422 were treated with allopurinol (Group A), 4141 with benzbromarone (Group B), and 2484 with both drugs (Group A/B) during the follow-up period. Our results showed the incidence of CAD after adjusting for covariates for Group A, Group B, and Group A/B did not significantly differ from the comparison group. However, after adjustment for covariates in dose-response analyses, treatment with over 270 defined daily doses (DDDs) of allopurinol, and over 360 DDDs of benzbromarone, was associated with a significantly reduced risk of CAD. Conclusion We found that the use of allopurinol and benzbromarone, whether alone or in combination, had a linear dose-response relationship between the numbers of defined daily doses and the risk of CAD, especially in higher DDDs.
Databáze: OpenAIRE
Externí odkaz: